ART3 regulates triple-negative breast cancer cell function via activation of Akt and ERK pathways

Area of Science:

• Oncology
• Molecular Biology
• Biochemistry

Background:

• Triple-negative breast cancer (TNBC) lacks targeted therapies due to poorly understood biology.
• Current treatment for TNBC relies solely on chemotherapy.

Purpose of the Study:

• To investigate the role of human ecto-ADP-ribosyltransferase 3 (ART3) in TNBC.
• To determine if ART3 can serve as a diagnostic marker or therapeutic target for TNBC.

Main Methods:

• Analysis of published gene expression datasets.
• Immunohistochemistry and immunoblotting to assess ART3 protein levels in TNBC tissues and cell lines.
• In vitro cell culture experiments and in vivo xenograft models to evaluate ART3 function.
• Western blot analysis to assess signaling pathway activation.

Main Results:

• ART3 expression is significantly associated with the basal-like breast cancer subgroup, which largely overlaps with TNBC.
• ART3 protein is significantly overexpressed in human TNBC tumors and cell lines.
• ART3 overexpression enhances breast cancer cell proliferation, invasion, and survival in vitro and tumor growth in vivo.
• ART3 overexpression activates AKT and ERK signaling pathways.

Conclusions:

• ART3 is a critical marker for triple-negative breast cancer.
• ART3 plays a functional role in promoting TNBC progression.
• ART3 represents a potential therapeutic target for TNBC.